Market Overview:
Global Psoriasis Drug Market size and share is currently valued at USD 29.5 billion in 2024 and is anticipated to generate an estimated revenue of USD 56.96 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 10.8% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 – 2034
Psoriasis is a chronic autoimmune disease that accelerates the lifecycle of skin cells, leading to inflammation and the development of thick, silvery scales. It is non-contagious but can cause serious physical and psychological distress. There are several forms of psoriasis, including plaque, guttate, inverse, pustular, and erythrodermic, with plaque psoriasis being the most common. Over recent years, the treatment landscape for psoriasis has evolved significantly, shifting from traditional topical agents and phototherapy to advanced biologic drugs and systemic treatments that target immune system pathways.
The growing pipeline of biologics, combined with increasing clinical approvals, is expanding the therapeutic arsenal available to dermatologists and healthcare providers. These biologics target specific immune markers such as TNF-alpha, interleukin-12, interleukin-23, and interleukin-17, offering improved disease control and better patient quality of life.
Growth Drivers:
Several key factors are driving the expansion of the psoriasis drug market:
- Rising prevalence of autoimmune disorders: The global increase in autoimmune diseases, including psoriasis and psoriatic arthritis, has significantly raised the demand for specialized treatments. Early diagnosis and increased healthcare access have made it possible to identify more cases and begin treatment sooner.
- Advancements in biologics and personalized medicine: The introduction of biologic drugs has revolutionized psoriasis treatment. These medications, derived from living organisms, target specific components of the immune system and provide longer-lasting and more targeted relief than traditional drugs. Ongoing innovation in monoclonal antibodies and gene-based therapies continues to expand treatment choices.
- Increased awareness and improved diagnosis: Patient awareness campaigns and growing dermatological education among healthcare professionals are helping to reduce the time between disease onset and treatment. This increased recognition leads to a higher rate of prescriptions and demand for effective therapies.
- Pipeline development and regulatory support: Pharmaceutical companies are investing heavily in R&D to discover novel drugs and delivery mechanisms. Favorable regulatory policies and accelerated drug approval processes are also contributing to quicker commercialization of promising treatments.
Key Companies:
The global psoriasis drug market is characterized by the presence of several prominent players who are investing in research, strategic collaborations, and product launches to strengthen their market positions:
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- LEO Pharma A/S
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- UCB S.A.
Psoriasis Drug Industry Developments:
- November 2024 – AbbVie announced the continued expansion of indications for its leading psoriasis treatment, Skyrizi. This development further solidifies the drug’s market position and underscores AbbVie’s commitment to broadening therapeutic options for psoriasis patients.
- November 2024 – Johnson & Johnson reported progress in advancing its dermatology pipeline, highlighted by icotrokinra, an oral treatment that successfully met its primary endpoints in late-stage clinical trials. This innovation represents a significant step forward in the company’s efforts to deliver next-generation therapies for psoriasis.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:
https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market
Market Segmentation:
Psoriasis Drug Market, Class Outlook (Revenue, USD Billion, 2020-2034)
- Tumor Necrosis Factor Inhibitors
- Interleukin Inhibitors
- Vitamin D Analogues
- Corticosteriods
- Others
Psoriasis Drug Market, Treatment Outlook (Revenue, USD Billion, 2020-2034)
- Topicals
- Systemic
- Biologics
Psoriasis Drug Market, Route of Administration Outlook (Revenue, USD Billion, 2020-2034)
- Oral
- Parenteral
- Topical
Psoriasis Drug Market, Type Outlook (Revenue, USD Billion, 2020-2034)
- Psoriatic Arthritis
- Plaque Psoriasis
- Others
Psoriasis Drug Market, Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Regional Analysis:
- North America: This region holds a dominant position in the global psoriasis drug market due to advanced healthcare infrastructure, strong reimbursement policies, and the presence of major pharmaceutical companies. The United States, in particular, has a high prevalence of psoriasis and a well-established approval and distribution system for biologics.
- Europe: Western European countries are also major contributors to the market. High healthcare expenditure, early adoption of novel therapies, and strong public awareness programs drive growth across Germany, the UK, and France.
- Asia-Pacific: Expected to witness the fastest growth in the coming years. Rising healthcare investment, increasing access to dermatological care, and a growing patient pool in countries like China and India are contributing to market expansion. Moreover, local pharmaceutical companies are investing in the development of cost-effective biosimilars.
- Latin America and the Middle East & Africa: These regions are gradually expanding their market shares. While limited access and healthcare funding pose challenges, ongoing efforts to improve healthcare delivery and awareness are likely to result in steady growth.
Conclusion:
The psoriasis drug market is poised for dynamic growth as the demand for innovative and effective treatment options continues to rise. With increased research into immune system pathways and patient-centric treatment strategies, the future of psoriasis management looks increasingly promising. Key players in the industry are expected to continue driving progress through collaborations, pipeline development, and greater global outreach, ensuring that patients have access to the latest and most effective therapies.
More Trending Latest Reports By Polaris Market Research:
Propylene Glycol Market – update